Geptanolimab is under clinical development by Apollomics and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Geptanolimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Geptanolimab overview
Geptanolimab (CBT-501) is under development for the treatment of cancers such as ovarian cancer, colorectal cancer, gastric cancer, soft tissue sarcoma, ALK-negative anaplastic large cell lymphoma, endometrial cancer, spongioblastoma, non-small cell lung cancer, mesothelioma, esophageal cancer, nasopharyngeal cancer, gastroesophageal junction adenocarcinoma. It is administered through intravenous infusion. The drug candidate is an IgG4 humanized monoclonal antibody against programmable death-1 (PD-1).
It was also under development for the treatment of metastatic hepatocellular carcinoma, cervical cancer, thymic carcinoma, metastatic renal cell carcinoma, primary mediastinal B-cell lymphoma and peripheral T-cell lymphoma, Bladder Cancer, Esophageal Cancer, Head And Neck Cancer, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Liver Cancer, Lymphoma, Melanoma, Natural Killer Cell Lymphomas, Renal Cell Carcinoma.
Apollomics overview
Apollomics is a biotechnology company that discovers and develops oncology therapies. It is investigating APL-101, a novel small molecule c-Met inhibitor (c-METi) that targets the c-Met-dysregulated pathway in gastric, hepatic, pancreatic and lung tumors; and APL-102, an oral multi-kinase inhibitor (mKi) targeting receptor tyrosine kinase (RTKs) and serine or threonine-kinases in liver, breast, colorectal, gastric cancers. The company is also evaluating APL-106 against acute myeloid leukemia (AML); APL-108 to treat multiple myeloma (MM); APL-501 and APL-102 targeting solid tumors; APL-502 and APL-801 against multiple tumors; and APL-810 for gastroenterological cancers. It operates in Taiwan and the US. Apollomics is headquartered in Foster City, California, the US.
For a complete picture of Geptanolimab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
